Algodx AB

Algodx AB specializes in advanced medical devices focused on gastrointestinal diagnostics. Their primary product, the NAVOYCDS, is designed for detecting and analyzing conditions like inflammatory bowel disease and celiac disease through molecular diagnostics. This device leverages specialized testing to provide precise diagnostic insights for healthcare providers.

Algodx AB is based in the United States, which means its devices are subject to FDA regulations. The NAVOYCDS, for example, is classified as a Class II device under FDA guidelines, indicating it poses moderate risk and requires compliance with specific controls to ensure safety and effectiveness. The company’s U.S. location also means its devices are listed in the FDA’s 510(k) clearance registry, where regulatory submissions and approvals are documented.

Algodx AB’s devices, such as the NAVOYCDS, are listed in the FDA’s 510(k) clearance registry. This registry is important because it provides transparency into the device’s regulatory history, including the premarket notification process required for Class II devices. Listing here confirms the device has met FDA requirements for safety and performance before entering the market, though it does not imply ongoing approval—individual devices must continue to comply with post-market obligations.

Algodx AB’s devices, including the NAVOYCDS, are classified as Class II under FDA regulations. This classification indicates that while the devices pose a moderate risk, they require special controls beyond general controls to ensure their safety and effectiveness. Special controls may include performance standards, post-market surveillance, or labeling requirements. The classification helps the FDA balance oversight with innovation by ensuring necessary safeguards are in place without the stricter scrutiny of Class III devices.